Arbutus biopharma corp (ABUS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue
Collaborations and contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32

107

2,847

3,035

2,310

3,520

3,327

3,578

1,144

3,689

2,488

2,961

2,844

2,132

Licensing fees, milestone and royalty payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

277

496

8,242

1,030

1,130

1,162

1,023

784

667

741

-

2

-

-

Revenue

1,491

1,618

3,061

653

679

1,678

1,587

1,244

1,436

2,534

6,892

1,039

235

-195

774

309

603

11,089

4,065

3,440

4,682

4,350

4,362

1,811

4,430

7,526

2,963

2,844

2,132

Non-cash royalty revenue

656

-

-

-

171

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Non-cash royalty revenue
Research and development

10,416

12,418

17,731

12,740

14,712

11,063

16,566

16,356

13,949

17,822

15,537

15,445

13,872

17,156

15,738

15,215

13,144

14,904

16,354

9,690

10,557

11,902

9,309

9,298

8,204

6,971

5,506

4,914

4,067

General and administrative

3,553

1,877

3,249

8,189

4,412

5,927

2,631

3,775

3,669

3,543

3,659

4,599

4,328

4,733

3,720

23,766

7,219

8,354

7,706

7,662

2,716

3,082

1,764

1,787

2,050

2,844

960

849

893

Depreciation

500

507

507

505

509

504

497

578

602

620

593

480

334

332

291

252

217

169

153

147

120

113

133

149

134

147

148

152

166

Gain on disposition of financial instrument

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,000

0

0

0

0

-

-

-

-

-

-

-

-

Foreign exchange gains (losses)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,728

-

-

-

-

-

Fair Value, Option, Changes in Fair Value, Gain (Loss)

-

-

-

-

-

-

-

-

-

0

0

0

-22

191

10

168

161

564

1,976

2,024

-1,223

2,560

-5,140

5,813

-13,616

-1,375

-2,435

-28

308

Change in fair value of contingent consideration

112

-52

-376

130

125

-1,035

-5,608

193

-848

213

197

-110

1,059

812

260

252

244

770

0

0

0

-

-

-

-

-

-

-

-

Site consolidation

57

123

182

-266

117

1,087

-492

2,581

1,621

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

361

9,295

-

0

0

-

-

-

-

-

Impairment of Intangible Assets (Excluding Goodwill)

-

-

43,836

-

-

-

14,811

-

-

-

0

-

-

-

0

156,324

-

-

37,990

0

-

-

0

-

-

-

-

-

-

Impairment of goodwill

-

-

22,471

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss Contingency, Loss in Period

-

-

6,486

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

14,638

14,580

94,462

21,168

19,875

18,581

34,013

23,290

19,841

62,783

19,789

20,524

18,534

257,244

19,749

195,557

20,580

24,444

62,203

17,860

22,688

15,559

11,206

11,234

10,388

9,962

6,614

5,915

5,126

Total operating expenses

-13,147

-12,962

-91,401

-20,515

-19,196

-16,903

-32,426

-22,046

-18,405

-60,249

-12,897

-19,485

-18,299

-257,439

-18,975

-195,248

-19,977

-13,355

-58,138

-14,420

-18,006

-11,209

-6,844

-9,423

-5,958

-2,436

-3,651

-3,071

-2,994

Loss from operations
Interest income

345

402

503

606

600

728

756

805

758

443

337

390

368

287

425

435

244

208

183

81

202

145

304

257

147

120

129

146

145

Interest expense

1,041

994

1,100

2

12

122

0

0

104

75

76

68

42

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Foreign exchange (losses) / gains

-18

-2

-25

60

8

-263

145

-359

-526

-157

1,233

798

427

-1,060

-795

33

2,942

5,503

11,801

-2,571

7,038

-

3,076

-

1,443

1,093

52

-61

-5

Gain (Loss) on Investments

-

-

0

0

-

-

0

24,884

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net equity investment loss

0

-

-3,512

-3,334

-4,651

-

-2,838

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other loss

-714

-11,692

-3,758

-2,800

-4,055

-1,346

3,671

25,137

976

-2

1,297

1,230

-328

-1,394

-620

384

4,103

5,505

13,960

-466

6,017

-

-1,760

-

-

-

-

-

-

Loss before income taxes

-13,861

-24,654

-95,159

-23,315

-23,251

-

-28,755

3,091

-

-

-11,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19,595

-194,864

-

-

-44,178

-14,886

-

-

-8,604

-

-

-

-

-

-

Income tax benefit

0

-

-12,656

-

0

-

-4,282

-

-

-

0

-

-

-

0

-64,864

-

-

-15,196

0

-

-

0

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-13,861

-

-82,503

-

-23,251

-

-24,473

-

-17,429

-35,931

-11,600

-18,255

-18,627

-218,695

-19,595

-130,000

-15,874

-6,861

-28,982

-14,886

-11,989

-6,168

-8,604

-6,081

-17,984

-2,598

-5,905

-3,014

-2,546

Items applicable to preferred shares:
Dividend accretion of convertible preferred shares

2,978

2,880

2,792

2,762

2,715

2,647

2,567

2,541

2,336

911

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shares

-16,839

-27,534

-85,295

-26,077

-25,966

-20,896

-27,040

550

-19,765

-36,842

-11,600

-18,255

-18,627

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in USD per share)

-

-

-

-0.46

-

-

-

0.01

-

-

-

-0.33

-

-

-

-

-

-

-

-

-

-

-

-

-0.91

-

-

-

-

Diluted (in USD per share)

-

-

-

-0.46

-

-

-

0.01

-

-

-

-0.33

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and dilutive (in USD per share)

-0.25

-

-1.50

-

-0.47

-

-0.49

-

-0.36

-

-0.21

-

-0.34

-

-0.37

-2.47

-0.31

-

-0.57

-0.27

-0.40

-

-0.39

-0.28

-

-

-0.41

-0.21

-0.18

Net loss per common share
Basic (in shares)

-

-

-

56,805

-

-

-

55,211

-

-

-

54,647

-

-

-

-

-

-

-

-

-

-

-

-

19,801

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

-

56,805

-

-

-

56,487

-

-

-

54,647

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

67,683

-

56,850

-

55,740

-

55,421

-

55,071

-

54,877

-

54,307

-

53,652

52,716

51,400

-

50,756

54,255

30,208

-

22,159

22,063

-

-

14,511

14,406

14,344

Unrealized gain on available-for-sale securities

251

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive income
Currency translation adjustment

0

-

-

-

-22

-

-

-

-

-

-

-

-

-

-

-

-

-9,820

-10,101

3,223

-9,174

-3,277

-4,827

3,774

-2,159

-1,733

710

-1,236

-876

Comprehensive loss

-13,610

-

-

-

-23,273

-

-

-

-

-

-

-

-

-

-

-

-

-16,681

-39,083

-11,663

-21,163

-9,445

-13,431

-2,307

-20,143

-4,331

-5,195

-4,250

-3,422

Collaboration And Contracts [Member]
Revenue

835

-

-

-

508

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-